CA2019363A1 - Adn et son utilisation - Google Patents

Adn et son utilisation

Info

Publication number
CA2019363A1
CA2019363A1 CA2019363A CA2019363A CA2019363A1 CA 2019363 A1 CA2019363 A1 CA 2019363A1 CA 2019363 A CA2019363 A CA 2019363A CA 2019363 A CA2019363 A CA 2019363A CA 2019363 A1 CA2019363 A1 CA 2019363A1
Authority
CA
Canada
Prior art keywords
pacap38
dna
protein
protective group
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2019363A
Other languages
English (en)
Other versions
CA2019363C (fr
Inventor
Haruo Onda
Akira Arimura
Chiharu Kimura
Chieko Kitada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP02039841A external-priority patent/JP3034894B2/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CA2019363A1 publication Critical patent/CA2019363A1/fr
Application granted granted Critical
Publication of CA2019363C publication Critical patent/CA2019363C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA002019363A 1989-06-20 1990-06-20 Adn et son utilisation Expired - Lifetime CA2019363C (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP155791/1989 1989-06-20
JP15579189 1989-06-20
JP25992489 1989-10-06
JP259924/1989 1989-10-06
JP28477189 1989-11-02
JP284771/1989 1989-11-02
JP39841/1990 1990-02-22
JP02039841A JP3034894B2 (ja) 1989-06-20 1990-02-22 新規ｄｎａおよびその用途

Publications (2)

Publication Number Publication Date
CA2019363A1 true CA2019363A1 (fr) 1990-12-20
CA2019363C CA2019363C (fr) 2000-05-30

Family

ID=27460824

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002019363A Expired - Lifetime CA2019363C (fr) 1989-06-20 1990-06-20 Adn et son utilisation

Country Status (5)

Country Link
US (2) US5198542A (fr)
EP (1) EP0404034B1 (fr)
AT (1) ATE127844T1 (fr)
CA (1) CA2019363C (fr)
DE (1) DE69022297T2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077764C (fr) * 1990-03-17 2002-12-10 Nobuhiro Suzuki Anticorps contre la peptide activant l'adenylate-cyclase de l'hypophyse, et son utilisation
EP0467279A3 (en) * 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US5521069A (en) * 1990-08-10 1996-05-28 Takeda Chemical Industries, Ltd. Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof
EP0470604A3 (en) * 1990-08-10 1992-12-09 Takeda Chemical Industries, Ltd. Pacap38, proteine with adenylate cyclase activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
US5695954A (en) * 1993-05-14 1997-12-09 University Of Victoria Innovation & Development Corporation DNA encoding two fish neuropeptides
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
US6165755A (en) * 1997-01-23 2000-12-26 University Of Victoria Innovation And Development Corporation Chicken neuropeptide gene useful for improved poultry production
EP1068347A1 (fr) * 1998-04-03 2001-01-17 Millennium Pharmaceuticals, Inc. Procedes et compositions servant a diagnostiquer et a traiter des maladies neuropsychiatriques
AR036400A1 (es) 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
JP4783013B2 (ja) 2002-07-30 2011-09-28 ステム セル セラピューティクス インコーポレイテッド 多能性神経幹細胞からの希突起神経膠細胞産生
CA2492442A1 (fr) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
AU2003283004A1 (en) 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
CA2556266A1 (fr) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Utilisation de l'hormone de luteinisation (lh) et de la gonadotropine chorionique (hcg) pour la proliferation de cellules souches neuronales et la neurogenese
WO2006012394A1 (fr) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Traitement du dysfonctionnement renal et du myelome multiple a l'aide de composes pacap
CA2582567A1 (fr) * 2004-10-07 2006-04-13 Stem Cell Therapeutics Corp. Stimulation de la proliferation de cellules souches pluripotentes par administration de composes associes a la gestation
WO2007036033A1 (fr) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Regulation par la prolactine de la proliferation des cellules precurseurs d'oligodendrocytes
WO2007106987A1 (fr) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Régimes de dosage continu pour agents de prolifération des cellules souches nerveuses et agents de différentiation desdites cellules
CA2779496A1 (fr) 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogues de polypeptide d'activation d'adenylate cyclase hypophysaire (pacap) et procedes pour leur utilisation
US10899834B2 (en) 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
US20220202905A1 (en) * 2019-05-14 2022-06-30 Senju Pharmaceutical Co., Ltd. Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity

Also Published As

Publication number Publication date
US5198542A (en) 1993-03-30
EP0404034B1 (fr) 1995-09-13
CA2019363C (fr) 2000-05-30
DE69022297D1 (de) 1995-10-19
EP0404034A2 (fr) 1990-12-27
EP0404034A3 (fr) 1991-07-17
DE69022297T2 (de) 1996-02-22
US5326860A (en) 1994-07-05
ATE127844T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
CA2019363A1 (fr) Adn et son utilisation
DE278776T1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein.
EP0366016A3 (en) Endothelin dna and use thereof
AU595290B2 (en) Process for producing human epidermal growth factor and analogs thereof
DE93619T1 (de) Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer.
TW427905B (en) Aqueous pharmaceutical composition of nerve growth factor
IE881755L (en) Novel proteins with factor viii activity, process for their¹preparation using genetically engineered cells and¹pharmaceutical compositions containing them
CA2024629A1 (fr) Proteine morphogenique osseuse dactylethre laevis, adn l'encodant et son utilisation
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
GR3026263T3 (en) Epithelins: novel cysteine - rich growth modulating proteins
DK1396542T3 (da) P-selectin ligand protein
DE69012377D1 (de) Polypeptid und dessen Herstellung.
WO1995030001A3 (fr) Nouvelle proteine ligand de p-selectine
EP0251730A3 (fr) Production de lysozyme humain
ES2012128A6 (es) Metodo de tratar plantas con acidos organicos que contienen azufre.
EP0315118A3 (fr) ADN codant pour endothéline et son utilisant
EP0193910A3 (fr) Synthèse d'un dérivé du "GRF" et peptides intermédiaires
AU1090688A (en) Synthetic porcine growth hormone
CA2051010A1 (fr) Proteine de recepteur a l'hormone-chorionique gonadotropin luteinisante humaine, adn et leur utilisation
AU7880987A (en) Human B-cell differentiation factor and process of producing said factor
AU6860294A (en) New chondrocyte proteins
EP0191869A4 (fr) Derive de calcitonine de poisson, son procede de preparation et systeme genique relatif.
CA2089111A1 (fr) Agent mitogene des muscles lisses et adn isole l'encodant
EP0446361A4 (en) Polypeptide, production thereof, and pharmaceutical composition and cosmetic containing said polypeptide
EP0249854A3 (fr) Polypeptide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202